



05-15-01

T

Box 8E91

03 20 01
#4

DI-5585L (BXTD 9000.1)
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of Brendan F. Murphy

Serial No. 09/805,337

Filed: March 13, 2001

Confirmation No.: 1925

For: A NOVEL FACTOR-H RELATED PROTEIN 5 AND ANTIBODIES THERETO

May 14, 2001

**LETTER IN RESPONSE TO NOTICE TO COMPLY
WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR
AMINO ACID SEQUENCE DISCLOSURES**

TO THE COMMISSIONER OF PATENTS AND TRADEMARKS

Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures" dated April 23, 2001, enclosed herewith is a copy of the Notice to Comply, a substitute copy of the computer readable form (CRF) of the sequence listing, a substitute paper copy of the sequence listing and a statement under 37 CFR §§ 1.821(g) and 1.825(b). No new matter has been added to the specification.

Applicant does not believe that any fees are due with this response; however, any fee deficiency may be charged to Deposit Account No. 19-1345.

Respectfully submitted,

James E. Butler, Ph.D., Reg. No. 40,931
SENNIGER, POWERS, LEAVITT & ROEDEL
One Metropolitan Square, 16th Floor
St. Louis, Missouri 63102
(314) 231-5400

JEB/mkd

*Enclosures

Express Mail Label No.: EL739385221US




UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/805,337	03/13/2001	Brendan F. Murphy	DI-5585L (BXTD 9000.1)

Charles R. Mattenson
Corp. Counsel, Renal Div.
Baxter Healthcare Corp.
One Baxter Parkway, DF3-3E
Deerfield, IL 60015-4633



CONFIRMATION NO. 1925

FORMALITIES LETTER



OC000000005994270

Date Mailed: 04/23/2001

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE

THIS PAGE BLANK (USPTO)